Want to see FR:NANO full AI Analyst Report?
Nanobiotix (NANO) Stock Price & Analysis
NANO Stock Chart & Stats
- Day’s Range
- EUR 28.06 - EUR 30.60
- 52-Week Range
- EUR 15.50 - EUR 47.66
- Previous Close
- EUR 30.32
- Volume
- N/A
- Average Volume (3M)
- 223.59K
- Market Cap
- EUR 1.43B
- Enterprise Value
- EUR 1.56B
- Total Cash (Recent Filing)
- EUR 110.89M
- Total Debt (Recent Filing)
- EUR 106.61M
- Price to Earnings (P/E)
- ―
- Beta
- 0.59
- Next Earnings
- Apr 27, 2027 (Est.)
- EPS Estimate
- 0.05
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Platform-Based Oncology Innovation
The NBTXR3 platform addresses a meaningful oncology need by seeking to improve the effectiveness of established radiotherapy. If clinical development succeeds across multiple solid-tumor indications, one technology could support broader commercial opportunities and provide a differentiated foundation for future partnerships.
2025 Revenue Recovery
The sharp 2025 revenue increase indicates that Nanobiotix has demonstrated some ability to generate greater commercial or collaboration-related income. Although the historical pattern is uneven, sustained revenue expansion would improve operating leverage and help fund development of its oncology platform over time.
High Gross Margin Profile
A 100% gross margin suggests that recognized 2025 revenue carried limited direct costs, which could provide attractive incremental economics if revenue becomes more consistent. This creates potential for future operating leverage, although the benefit depends on controlling ongoing development and corporate expenses.
Bears Say
Persistent Unprofitability
Continued large losses show that Nanobiotix has not yet converted its technology and revenue activity into sustainable earnings. Persistent unprofitability can constrain strategic flexibility, increase dependence on financing, and make future performance highly dependent on successful development and commercialization milestones.
Ongoing Cash Burn
Consistent operating and free-cash-flow deficits indicate that the company is consuming cash rather than funding operations internally. Because the 2025 improvement reflects a smaller burn rather than positive generation, Nanobiotix remains reliant on external capital to sustain clinical development and business activities.
Negative Equity And Rising Debt
A persistently negative equity base materially weakens financial flexibility and makes leverage harder to manage. Rising debt adds to the pressure by increasing obligations while the company remains loss-making, potentially limiting its ability to absorb setbacks or fund growth without additional external support.
Nanobiotix News
NANO FAQ
What was Nanobiotix’s price range in the past 12 months?
What is Nanobiotix’s market cap?
When is Nanobiotix’s upcoming earnings report date?
How were Nanobiotix’s earnings last quarter?
Is Nanobiotix overvalued?
Does Nanobiotix pay dividends?
What is Nanobiotix’s EPS estimate?
How many shares outstanding does Nanobiotix have?
What happened to Nanobiotix’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Nanobiotix?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Laurent Levy
- Employees
- 98
- Website
- www.nanobiotix.com
- Address
- 60 rue de Wattignies, Paris, IF, 75012, FR
Nanobiotix (NANO) Earnings & Revenues
NANO Earnings Call
Earnings Call SentimentPositive
The call presented several concrete operational and financial improvements: a strengthened balance sheet via nondilutive financing, a meaningful reduction in R&D expense tied to the Janssen transfer, a much smaller net loss, progressing late-stage trials run by J&J (Phase III head & neck and randomized Phase II lung) and clear advancement of the Curadigm platform (patents, MTAs, GMP/CMC steps). However, many positives are tempered by important caveats: the 2025 revenue improvement is substantially a one-time accounting adjustment, early clinical data (CONVERGE safety lead-in) are from a very small cohort, key development and commercialization decisions rest with J&J, and the cash runway depends on future contingent payments. Overall, operational momentum and improved financial flexibility weigh strongly in favor of a positive view, but execution and J&J-dependent milestones remain critical risks.
View all FR:NANO earnings summariesNANO Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 3 | 10 |
| Technical Analysis | 3 | 3 | 4 |
| Moving Averages | 6 | 0 | 6 |
